Buprenorphine Induction in a Patient on Full Agonist Therapy
A 34-year-old man with severe opioid use disorder (fentanyl, ~1 g/day, intranasal) presents requesting treatment. He last used fentanyl 10 hours ago. COWS score is 9. He has been on methadone 80 mg/day for 2 years but relapsed 3 months ago and has been using fentanyl on top. He has mild hepatic impairment (ALT 68), is HCV antibody positive with undetectable RNA, and has no prior buprenorphine exposure. He wants to "get off everything" and asks about rapid detox and naltrexone implants.
1. What are the key risks of buprenorphine induction in this patient, and how do you sequence it?
Read the worked answer
Key risk: precipitated withdrawal. He is on methadone 80 mg (long half-life) and using fentanyl (lipophilic, long tissue half-life), so his opioid burden is high. COWS 9 is too low to start buprenorphine safely; induction requires moderate withdrawal (COWS ≥ 12–13).
Sequencing:
- Do not stop methadone abruptly without a plan; coordinate with the methadone program.
- Transition strategy: either (a) taper methadone to ≤ 30–40 mg before buprenorphine transition, or (b) use low-dose buprenorphine induction (“microdosing”) while continuing the full agonist, which avoids precipitated withdrawal. Microdosing is increasingly used for fentanyl/methadone transitions.
- Fentanyl requires longer abstinence (often 24–72 h) before standard induction due to tissue storage.
- Start low (e.g., 2–4 mg) and titrate; observe for precipitated withdrawal (agitation, vomiting, diarrhea, mydriasis, piloerection, anxiety).
- Hepatic impairment: buprenorphine is hepatically metabolized; monitor LFTs, though buprenorphine is relatively safe in mild–moderate impairment.
Rapid detox and naltrexone implants are not recommended - high relapse and overdose risk, especially with fentanyl.
2. How do you counsel him about "getting off everything" and about naltrexone?
Read the worked answer
Explain that opioid use disorder is a chronic condition and that medication for opioid use disorder (MOUD) - buprenorphine or methadone - reduces mortality and is first-line. Detox alone is associated with high relapse and loss of tolerance → overdose death.
About naltrexone:
- It is an antagonist and requires full detoxification (7–10 days opioid-free); with fentanyl this is difficult and relapse-prone.
- Implants are not standard first-line and carry risks (site reactions, inadequate dosing, relapse after removal).
- Extended-release injectable naltrexone (XR-NTX) is an option after complete detox, but buprenorphine/methadone are preferred for severe OUD with high fentanyl use.
Discuss goals: abstinence is not the only valid goal; retention in treatment and reduced illicit use are meaningful outcomes. Offer shared decision-making, and revisit the plan as his goals evolve.
Overdose education and naloxone should be provided regardless of treatment choice.
3. What psychosocial and safety supports should accompany pharmacotherapy?
Read the worked answer
- Behavioral treatment: cognitive behavioral therapy, contingency management (if available), motivational interviewing, and peer support.
- Harm reduction: naloxone kit and training, fentanyl test strips where legal, safe-use education, and overdose response planning.
- Medical: HCV monitoring (RNA undetectable - confirm), HIV testing, STI screening, vaccination, LFT monitoring, and pain assessment.
- Psychiatric comorbidity: screen for depression, anxiety, PTSD, and suicide risk.
- Social: housing, employment, transportation, and childcare needs; connect with syringe services and community resources.
- Care coordination between the methadone program, buprenorphine prescriber, and primary care to avoid gaps.
- Follow-up within days of induction, with a clear relapse and overdose plan.